SCHEMBL6179432

SCHEMBL6179432

COC(=O)c1[nH]c2c(O)cc(NC(=O)c3cc4cc(NC(=O)c5cc6ccocc-6c5)ccc4[nH]3)c(CCCl)c2c1C(=O)OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.36
PYGL P06737 4/20 0.34
LEF1 Q9UJU2 1/20 0.34
KDM4E B2RXH2 5/20 0.34
NPC1 O15118 3/20 0.34
MAPT P10636 3/20 0.34
RAB9A P51151 2/20 0.34
KMT2A Q03164 1/20 0.34
HDAC2 Q92769 1/20 0.34
TP53 P04637 1/20 0.33
ALDH1A1 P00352 2/20 0.33
PRNP P04156 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BRD4 O60885 1/20 0.32
BRD2 P25440 1/20 0.32
CREBBP Q92793 1/20 0.32
NHERF1 O14745 1/20 0.32
MMP13 P45452 1/20 0.32
HRAS P01112 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734157 0.81 TP53 (0.42) KDM4ENPC1MAPTRAB9AKMT2A
SCHEMBL5735275 0.77 PYGL (0.39) LRRK2PYGLKDM4ENPC1MAPT
SCHEMBL5733235 0.77 HDAC2 (0.47) LRRK2PYGLHDAC2TP53NHERF1
SCHEMBL5734516 0.72 LRRK2 (0.38) LRRK2PYGLHDAC2TP53NHERF1
SCHEMBL5734528 0.72 LMNA (0.43) KDM4EMAPTKMT2ATP53ALDH1A1
SCHEMBL6180022 0.71 KMT2A (0.43) PYGLKDM4ENPC1MAPTRAB9A
SCHEMBL5732990 0.71 LRRK2 (0.38) LRRK2PYGLKDM4ENPC1MAPT
SCHEMBL24065590 0.69 HSP90AA1 (0.33)
SCHEMBL21944101 0.68 HSP90B1 (0.31)
SCHEMBL6245000 0.68 HDAC2 (0.34) PYGLKDM4ENPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320522-B1 COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS TAIHO PHARMACEUTICAL CO LTD (JP) 2005-11-23 EP disclosed
US-6660742-B2 Alkylation therapy; anticancer agent TAIHO PHARMACEUTICAL CO. LTD. (JP) 2003-12-09 US disclosed
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins MEDIMMUNE LIMITED (GB) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins DDB1, ERCC2, SSU72 LRRK2 3088/4885PYGL 4444/4885LEF1 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.